Category: Health

Categories
Health

Some Child Meals Might Comprise Poisonous Metals, U.S. Studies

Some Baby Food May Contain Toxic Metals, U.S. Reports

While heavy metals are naturally found in some grains and vegetables, levels can be increased when food manufacturers add other ingredients to baby foods such as enzymes as well as high-metal vitamin and mineral mixtures, the report said. Manufacturers rarely test ingredients for mercury.

On August 1, 2019, investigators also described a so-called “secret” presentation by the industry to the FDA. Representatives from Hain told the regulatory authorities that testing only individual ingredients in baby food led to an underestimation of the heavy metal content in the end product.

For example, the inorganic arsenic in Hain’s finished baby formula was between 28 and 93 percent higher than estimated by testing the individual ingredients. Half of the brown rice products were over 100 parts per billion, according to the report.

Robin Shallow, a spokeswoman for Hain Celestial, said the company has not yet seen the report and cannot comment on the details, adding that Hain is continuously developing its internal testing procedures in collaboration with the FDA to ensure our products are safe safety and nutrition exceed standards, including screening for harmful amounts of substances that occur naturally. “

Beech nut, which used ingredients high in arsenic to improve properties like “crumb smoothness” in some products, set very liberal thresholds for arsenic and cadmium in their additives, according to the report: 3,000 ppb cadmium in additives such as vitamin mix and 5,000 ppb lead in one Enzyme additive called BAN 800.

The company used cinnamon, which contained 886.9 ppb lead, according to the report. The company’s standards for cadmium and lead in additive ingredients “far exceed any existing legal standard,” investigators said. Other added spices such as oregano and cumin were also high in lead.

For comparison, the FDA has stated that lead should not exceed 5 ppb in bottled water, 50 ppb in juices, and 100 ppb in candy. Cadmium shouldn’t exceed 5 ppb in bottled water, the agency said. The European Union limits cadmium in infant formula to 15 ppb.

Categories
Health

UK trial experiments with mixing Covid vaccines

Pfizer PFE Q4 2020 earnings fall short, but revenue beats expectations

Empty vials containing the Pfizer COVID-19 vaccine are seen at a drive-through vaccination facility operated by the Lake County Health Department in Groveland, Florida on January 28, 2021.

Paul Hennessy | NurPhoto | Getty Images

LONDON – A study is being launched in the UK to see if using different Covid-19 vaccines for first and second dose will help make nationwide immunization programs more flexible.

The study, led by Oxford University and conducted by the National Immunization Schedule Evaluation Consortium, will assess the feasibility of using a vaccine for the initial “prime” vaccination other than the subsequent “booster” vaccination.

It is hoped that the study will help policymakers understand whether mixing different Covid vaccines could be a viable way to increase the flexibility of vaccination programs, and whether it could even offer better protection.

“If we show that these vaccines can be used interchangeably on the same schedule, it will greatly increase the flexibility of vaccine delivery and could provide guidance on how protection against new strains of the virus can be enhanced,” said Matthew Snape, chief investigator of the process and associate Professor of Pediatrics and Vaccine at Oxford University said Thursday.

Officially known as the “COVID-19 Heterologous Prime Boost” study but dubbed the “Com-Cov” study, the study will recruit over 800 volunteers aged 50 and over in England to study the four different combinations of Prime and to evaluate booster vaccination.

A first dose of the Oxford AstraZeneca vaccine will be tested, followed by a booster with either the Pfizer BioNTech vaccine or another dose of the Oxford AstraZeneca vaccine. Research will also look at a first dose of the Pfizer BioNTech vaccine, followed by a booster with either the Oxford AstraZeneca vaccine or another dose of the Pfizer BioNTech vaccine. The British government has called the process a “world first”.

These are evaluated in two different dosing schedules: at an interval of four weeks to allow early intermediate reading of the data, and at an interval of 12 weeks. This latter dose interval is the current UK vaccination policy: delaying the second dose means that more people can get their first vaccines sooner with a shortage of vaccinations.

Although the policy has been viewed as controversial, some experts fear that it could make vaccines used in the UK less effective. So far only the candidates from the University of Oxford-AstraZeneca and Pfizer-BioNTech are used. The Moderna shot is due to be added to the vaccine basket later this spring.

However, Oxford University published a study on Wednesday that showed that a 12 week delay between the first and second dose of the AstraZeneca sting increased the vaccine’s effectiveness.

The researchers found that the shot was 76% effective at preventing symptomatic infection for three months after a single dose, and that the effectiveness rate increased to 82.4% if there was an interval of at least 12 weeks before the second dose. When the second dose was given less than six weeks after the first, the rate of effectiveness was 54.9%.

How the Com-Cov study will work

In the latest “Com-Cov” study, researchers will collect blood samples from volunteers from the study and monitor the effects of various dosage regimens on participants’ immune responses, as well as looking for additional side effects for the new vaccine combinations.

The study will last 13 months and was funded by the Vaccines Taskforce, established last April by the UK to coordinate efforts to research and manufacture a coronavirus vaccine, with £ 7 million of government funding (9, USD 5 million).

Professor Snape said the study was “tremendously exciting” before adding that “it will provide information that is critical to the launch of vaccines in the UK and globally”.

The richer countries are making every effort to vaccinate as many people as possible to limit the spread of infections and prevent hospitals from being overrun, which harms the economy.

Britain was hit hard by the pandemic, with cases spiking over the winter, aided by a more virulent variant of the virus that has emerged in south-east England and has now become a dominant strain in the country.

The UK currently has the fourth highest number of cases in the world with over 3.8 million confirmed infections. This comes from a record by Johns Hopkins University and recorded 109,547 deaths.

The UK government was quick to pre-order coronavirus vaccines from various manufacturers early last year and approve the vaccines currently in use. The vaccination program has been widely praised for its agility and range. The aim is to vaccinate 15 million people across the four top priority groups, including health and care workers, the elderly and the over 70s, and those who are considered to be extremely clinically at risk by mid-February.

The latest government data from Wednesday shows that just over 10 million people have received their first dose of vaccine and nearly 500,000 have received a second dose. The UK-made Oxford-AstraZeneca vaccine makes up the bulk of the UK vaccination program.

Professor Jonathan Van-Tam, deputy chief medical officer and senior responsible officer for the study, said the research may even show that alternating vaccines could increase the amount of antibodies needed to fight a possible Covid-19 infection.

“It’s even possible that the combination of vaccines may improve the immune response, resulting in even higher antibody levels that last longer. If this isn’t evaluated in a clinical trial, we just don’t know. This study will give us a better one Provide insight into how We can use vaccines to keep abreast of this dire disease, “he said.

The British vaccination minister Nadhim Zahawi told the BBC on Thursday that the country’s vaccination program will continue as usual for the time being: “At the moment we are not going to change anything,” Zahawi told the “Today” program.

“If you got a Pfizer BioNTech vaccine for your first dose, you got a Pfizer BioNTech vaccine for your second. If you had Oxford-AstraZeneca, you got Oxford-AstraZeneca for your second dose.”

Categories
Health

Within the Vaccine Scramble, Most cancers Sufferers Are Left Behind

In the Vaccine Scramble, Cancer Patients Are Left Behind

“This was a complete – I’m not going to say disaster, but it was pretty close,” said Dr. Hanny Al-Samkari, hematologist and clinical investigator at Massachusetts General Hospital and Harvard Medical School. Cancer patients get “mixed news,” he said, and the guidance they receive depends largely on their condition. Every day, he receives a barrage of messages from patients asking if they still qualify for the vaccine (in his state the answer is mostly no). They drove four hours to find a vaccination site. “It’s the Wild West,” he said.

He urged cancer patients to contact their doctors to coordinate the timing of the vaccine according to their treatment, unless they are in remission, have been treated a long time ago, or are receiving only hormonal treatment for breast or breast cancer Prostate cancer, said Dr. Tomasz Beer, professor in the School of Medicine at Oregon Health and Science University and assistant director of the school’s Knight Cancer Institute.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This may be the case for people who are charged a doctor’s visit fee with their vaccine, or for Americans who have certain types of health insurance that are not covered by the new regulations. When you get your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine from a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

For example, those receiving chemotherapy might have the best chances of developing an immune response if the vaccine is given if their white blood cell counts aren’t at their lowest levels, said Dr. Beer. The recommendations for patients with leukemia or lymphoma who are under treatment or who have recently had a bone marrow transplant are particularly complex and absolutely require consultation and coordination with an oncologist, he stressed.

While some are concerned about the risk of encountering a crowd at a mass vaccination site, Dr. Al-Samkari instructs patients to receive doses wherever they are available, as long as they wear masks and keep their distance from other people. “Fears are clearly well founded,” he said. “But we have to get shots in the arms.”

In general, people with cancer should get the vaccine “as soon as possible, wherever they can,” said Dr. Carol Ann Huff, clinical director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and one of the authors of the Cancer Network’s National Comprehensive Guidelines on Covid-19 Vaccines for Cancer Patients. There are some caveats: Patients on a bone marrow transplant or CAR-T therapy should wait at least three months before receiving the vaccine, she said.

However, depending on the level of virus transmission in the patient community, it may be safer to wait to receive the vaccine. If there is high levels of transmission in the community, “the risks might outweigh the benefits of waiting,” said Dr. Beer. Patients with active cancer should contact their oncologist before receiving the vaccine. He advised unless they are in remission, have been treated a long time ago, or are just receiving hormonal treatment for breast or prostate cancer.

Those who take part in cancer clinical trials have a grimmer guide to vaccination. Allyson Harkey, 46, from Maryland, has stage four kidney cancer and is in an immunotherapy study. She said her doctor wasn’t sure she should get the vaccine. The National Comprehensive Cancer Network guidelines generally recommend that patients receiving immunotherapy receive the vaccine as soon as it becomes available. However, you should consult with your doctor beforehand as there are so many different studies out there. She feels like she is in a state of limbo, waiting for more information – a process made more frustrating by what she thinks is a ticking clock. “My prognosis is not good. I probably have a few more years, ”she said. “It’s really hard to spend this time because I know I don’t have much time left, just in my house.”

Categories
Health

JPMorgan is constructive on Indonesia regardless of surging Covid instances within the nation

JPMorgan is positive on Indonesia despite surging Covid cases in the country

SINGAPORE – JPMorgan sees the outlook for Indonesia as positive, although the country is still grappling with rising Covid infections and the number of cases has topped a million lately.

The country’s young population is part of the reason for this optimism, said James Sullivan, head of ex-Japan Asian equity research at the investment bank.

“Demographically, Southeast Asia is very different from some of the developed countries we compare these countries with,” Sullivan told CNBC’s Squawk Box Asia on Wednesday.

In 2015, the average age of the Indonesian population was 28.5 years, according to Statista.

“Because they’re so much younger, they tend to tackle the mortality side of this conversation significantly better than some of the older, developed economies,” he said. “That’s a very important distinction when we think about it.”

As a result, lockdowns “may not be as necessary” in such countries – compared to places with significantly older populations that are at higher risk from Covid-19, the analyst said.

India as an example

To make his point clear, Sullivan used the example of India, a country that, according to Johns Hopkins University, ranks second in the world after the United States in terms of the number of Covid infections.

“There was long talk of infection rates in India until around August last year,” he said, adding that there were “very dire predictions” about the impact of the pandemic on the Indian economy.

These fears regarding India do not appear to have materialized as the daily number of Covid cases in the country has decreased significantly since then. Analysts have also said the economic recovery has been stronger than expected.

Still, according to Hopkins, Indonesia has had the highest number of Covid-19 cases in Southeast Asia.

As of Wednesday, Indonesia had more than 1.11 million coronavirus infections while at least 30,770 people had died from Covid-19, information from the country’s health ministry showed.

Other factors

In addition to Indonesia’s relatively young population, JPMorgan also sees “positive efforts” to stimulate growth across Indonesia’s economy, Sullivan said.

The government is pushing for a mutual fund called the Indonesia Investment Authority. According to reports, Indonesian President Joko Widodo plans to raise up to $ 100 billion.

Sullivan added that there has been a “significant recovery” in manufacturing, particularly in the export sector. In addition, the JPMorgan analyst cited the government’s vaccine efforts as another reason for its positive outlook.

Indonesia launched a Covid-19 vaccination program in January, which Reuters has named as one of the world’s largest campaigns. The country’s finance minister, Sri Mulyani Indrawati, recently told CNBC that it will take Indonesia at least a year to achieve “herd immunity” – which is when a large section of the population becomes immune to the disease.

– CNBC’s Yen Nee Lee contributed to this report.

Categories
Health

How New Vaccine Information Provides Hope for Spring, if Sufficient Individuals Get the Pictures

How New Vaccine News Gives Hope for Spring, if Enough People Get the Shots

Als Anfang November im ganzen Land Coronavirus-Infektionen zunahmen – und sich die Aussicht auf einen langen, dunklen Winter abzeichnete – war nicht klar, ob sich einer der in der Entwicklung befindlichen Impfstoffe durchsetzen würde.

Jetzt, drei Monate später, sieht das Bild ganz anders aus. Im ganzen Land werden zwei hochwirksame Covid-Impfstoffe eingeführt. Drei andere scheinen etwas weniger robust zu sein, bieten aber dennoch einen starken und in einigen Fällen vollständigen Schutz vor schweren Krankheiten und Todesfällen.

Alleine in der vergangenen Woche berichteten Novavax und Johnson & Johnson, dass ihre Impfstoffe einen guten Schutz bieten, auch gegen neue, ansteckendere Varianten des Coronavirus. Eine neue Analyse der Universität Oxford legt nahe, dass der mit AstraZeneca entwickelte Impfstoff die Übertragung verlangsamen kann und besonders gut funktioniert, wenn sich die zweite Dosis verzögert.

Nach einem Sputter-Start beschleunigt sich die Impfung in den USA: Mehr als 27 Millionen Amerikaner haben eine erste Dosis erhalten, und mehr als sechs Millionen wurden vollständig geimpft. Dieses Tempo hat sich so beschleunigt, dass Präsident Biden, der kritisiert wurde, dass das Ziel seiner Regierung, in seinen ersten 100 Tagen im Amt 100 Millionen Schüsse abzugeben, zu bescheiden war, letzte Woche das Ziel auf 150 Millionen Schüsse nach oben korrigierte.

“Wir haben einen langen Weg zurückgelegt”, sagte Akiko Iwasaki, Immunologe an der Yale University. “Wir leben immer noch mit tödlichen Krankheiten, weil wir nicht genug Menschen geimpft haben, aber sobald wir dies tun, wird sich die Art und Weise, wie wir mit diesem Virus leben und umgehen, wirklich ändern.”

Aber auch wenn es im Frühjahr und Sommer Grund zur Hoffnung gibt, bleiben viele Experten des öffentlichen Gesundheitswesens in den nächsten Monaten pessimistisch. Mehrere warnten, dass die Welt bei weitem nicht frei von einer Pandemie sei, bei der in den USA fast 450.000 Menschen und weltweit 2,2 Millionen Menschen ums Leben gekommen seien.

In reichen Ländern haben sich die Impfungen beschleunigt, aber ärmere Länder bleiben zurück. In den Vereinigten Staaten erhalten wohlhabendere weiße Einwohner häufiger Zugang zu dem Impfstoff als Schwarze und Latinos, die überproportional von der Pandemie betroffen sind.

Obwohl die Fälle in den Vereinigten Staaten in den letzten Wochen zurückgegangen sind, befinden sie sich immer noch auf einem Niveau, das fast doppelt so hoch ist wie der Höhepunkt des letzten Sommers, selbst wenn einige Großstädte wie Chicago und New York Speisen im Innenbereich und andere Aktivitäten eröffnen. Die Rücknahme von Beschränkungen kommt auch, da ansteckende neue Varianten den Globus umkreisen, von denen einige die Wirksamkeit der Impfstoffe zu verringern scheinen.

Dr. Eric Topol, Experte für klinische Studien bei Scripps Research in San Diego, erinnerte sich daran, dass er bereits im Dezember hoffnungsvoll war, dass die Pandemie in den USA bis Juni gezähmt werden könnte, dank der Flut ermutigender Impfstoffdaten. Aber als das Bild in den letzten Wochen klarer wurde, was die Bedrohung durch neue, ansteckendere Varianten des Virus betrifft, die sich in anderen Ländern ausbreiten, die in den Vereinigten Staaten aufgetaucht sind – insbesondere die Variante B.1.1.7, die erstmals in Großbritannien – sein Optimismus hat nachgelassen.

“Die Varianten haben alles verändert”, sagte Dr. Topol.

Vorläufige Studien haben gezeigt, dass die Impfstoffe von Pfizer, Moderna, Novavax und Johnson & Johnson gegen die Variante B.1.1.7 zu wirken scheinen und dass sie auch – wenn auch weniger – gegen die erstmals in Südafrika identifizierte Variante wirksam sind. Selbst im Fall dieser Variante zeigte die Studie von Johnson & Johnson, dass sie immer noch vor schweren Krankheiten schützt.

Einige der ersten Menschen, die geimpft wurden, sehen einen Weg aus der Pandemie.

Bei Bloom Senior Living, einer Kette von Seniorenwohneinrichtungen im Südosten und Mittleren Westen, haben Beamte an fünf ihrer neun Standorte nach und nach begonnen, ihre Türen für Besucher in Innenräumen wieder zu öffnen.

Diese Entscheidungen waren auf die Infektionsraten in der Gemeinde zurückzuführen, aber ein weiterer Faktor hat die Beamten von Bloom mit der Idee vertraut gemacht: 96 Prozent der Bewohner von Einrichtungen, die von Apothekenimpfungsteams besucht wurden, haben zugestimmt, einen Schuss zu bekommen.

“Es bedeutet alles für sie, ihre erwachsenen Kinder und hoffentlich schließlich ihre Enkelkinder sehen zu können – um das Gefühl zu haben, wieder ein Leben zu führen”, sagte Bradley Dubin, Direktor der Firma, die die Bloom-Einrichtungen besitzt.

Die Auswirkungen der US-Impfkampagne zeigen sich möglicherweise in den Daten. Die Anzahl der bestätigten Coronavirus-Fälle bei Pflegebewohnern ging in den ersten drei vollen Wochen, in denen Impfstoffe in Pflegeheimen verabreicht wurden, zurück. Dies geht aus Daten hervor, die Pflegeheime den Zentren für die Kontrolle und Prävention von Krankheiten melden. Es ist nicht klar, wie viel davon auf Impfungen zurückzuführen ist.

In Vermont, wo 85 Prozent der Menschen in Langzeitpflegeeinrichtungen zugestimmt haben, mindestens ihren ersten Impfstoff zu bekommen, sagten Beamte diese Woche, dass sie planen, die Besuchsbeschränkungen in diesen Häusern bald zu lockern, obwohl sie dies nicht festgelegt haben ein Datum dafür.

Die Impfkampagne in Pflegeheimen ist Teil einer Impfkampagne in den USA, die nach wochenlangen frustrierenden Verzögerungen an Dynamik gewonnen hat. Die Vereinigten Staaten geben derzeit durchschnittlich 1,3 Millionen Schüsse pro Tag ab, und in einigen Staaten wie Alaska und New Mexico haben mehr als 10 Prozent der Bevölkerung mindestens eine von zwei erforderlichen Dosen eines Impfstoffs erhalten.

Staatliche und lokale Gesundheitsbehörden richten Massenimpfaktionen durch, beispielsweise im Dodger Stadium in Los Angeles, und arbeiten mit der Nationalgarde und der Federal Emergency Management Agency zusammen. Die Kampagne wird auch zunehmend auf Apotheken ausgeweitet, in denen viele Amerikaner daran gewöhnt sind, Impfstoffe zu erhalten.

Auch an der Versorgungsfront gibt es hoffnungsvolle Anzeichen.

Am Dienstag kündigte die Bundesregierung an, den Staaten für die nächsten drei Wochen mindestens 10,5 Millionen Dosen Coronavirus-Impfstoffe zuzuteilen. Gleichzeitig spricht Moderna mit der Food and Drug Administration über die Befüllung der Durchstechflaschen mit 15 statt der derzeit 10 Dosen. Diese Änderung könnte die Produktion des Unternehmens um 50 Prozent steigern.

Darüber hinaus hat Pfizer angekündigt, bis Mai zwei Monate vor dem geplanten Termin 200 Millionen Dosen in die USA liefern zu können, da jetzt eine zusätzliche Dosis in den Impfstoffflaschen gezählt wird.

Covid19 Impfungen >

Antworten auf Ihre Impfstofffragen

Bin ich in meinem Bundesstaat für den Covid-Impfstoff berechtigt?

Derzeit können mehr als 150 Millionen Menschen – fast die Hälfte der Bevölkerung – geimpft werden. Aber jeder Staat trifft die endgültige Entscheidung darüber, wer zuerst geht. Die 21 Millionen Beschäftigten im Gesundheitswesen des Landes und drei Millionen Einwohner von Langzeitpflegeeinrichtungen waren die ersten, die sich qualifizierten. Mitte Januar forderten Bundesbeamte alle Bundesstaaten auf, die Berechtigung für alle über 65-Jährigen und für Erwachsene jeden Alters mit Erkrankungen zu öffnen, bei denen ein hohes Risiko besteht, dass sie schwer krank werden oder an Covid-19 sterben. Erwachsene in der Allgemeinbevölkerung stehen am Ende der Reihe. Wenn Gesundheitsbehörden von Bund und Ländern Engpässe bei der Verteilung von Impfstoffen beseitigen können, sind alle ab 16 Jahren bereits im Frühjahr oder Frühsommer förderfähig. Der Impfstoff wurde bei Kindern nicht zugelassen, obwohl derzeit Studien durchgeführt werden. Es kann Monate dauern, bis ein Impfstoff für Personen unter 16 Jahren verfügbar ist. Aktuelle Informationen zu den Impfrichtlinien in Ihrer Region finden Sie auf Ihrer staatlichen Gesundheitswebsite

Ist der Impfstoff frei?

Sie sollten nichts aus eigener Tasche bezahlen müssen, um den Impfstoff zu erhalten, obwohl Sie nach Versicherungsinformationen gefragt werden. Wenn Sie nicht versichert sind, sollten Sie den Impfstoff trotzdem kostenlos erhalten. Der Kongress hat in diesem Frühjahr ein Gesetz verabschiedet, das es Versicherern verbietet, eine Kostenteilung wie eine Zuzahlung oder einen Selbstbehalt anzuwenden. Es bestand aus zusätzlichen Schutzmaßnahmen, die es Apotheken, Ärzten und Krankenhäusern untersagten, Patienten, einschließlich nicht versicherter Patienten, in Rechnung zu stellen. Trotzdem befürchten Gesundheitsexperten, dass Patienten in Schlupflöcher geraten, die sie für Überraschungsrechnungen anfällig machen. Dies kann bei Personen der Fall sein, denen zusammen mit ihrem Impfstoff eine Arztbesuchsgebühr berechnet wird, oder bei Amerikanern, die bestimmte Arten der Krankenversicherung haben, die nicht unter die neuen Vorschriften fallen. Wenn Sie Ihren Impfstoff von einer Arztpraxis oder einer Notfallklinik erhalten, sprechen Sie mit ihnen über mögliche versteckte Kosten. Um sicherzugehen, dass Sie keine Überraschungsrechnung erhalten, ist es am besten, Ihren Impfstoff an einer Impfstelle des Gesundheitsministeriums oder in einer örtlichen Apotheke zu erhalten, sobald die Aufnahmen breiter verfügbar sind.

Kann ich wählen, welchen Impfstoff ich bekomme?Wie lange hält der Impfstoff? Brauche ich nächstes Jahr noch einen?

Das ist zu bestimmen. Es ist möglich, dass Covid-19-Impfungen genau wie die Grippeimpfung zu einem jährlichen Ereignis werden. Oder es kann sein, dass der Nutzen des Impfstoffs länger als ein Jahr anhält. Wir müssen abwarten, wie dauerhaft der Schutz vor den Impfstoffen ist. Um dies festzustellen, werden Forscher geimpfte Menschen aufspüren, um nach „Durchbruchsfällen“ zu suchen – jenen Menschen, die trotz Impfung an Covid-19 erkranken. Dies ist ein Zeichen für eine Schwächung des Schutzes und gibt Forschern Hinweise darauf, wie lange der Impfstoff hält. Sie werden auch die Spiegel von Antikörpern und T-Zellen im Blut geimpfter Personen überwachen, um festzustellen, ob und wann ein Auffrischungsschuss erforderlich sein könnte. Es ist denkbar, dass Menschen alle paar Monate, einmal im Jahr oder nur alle paar Jahre Booster benötigen. Es geht nur darum, auf die Daten zu warten.

Benötigt mein Arbeitgeber Impfungen?Wo kann ich mehr erfahren?

Hunderte Millionen zusätzlicher Impfstoffdosen von Johnson & Johnson, AstraZeneca und Novavax könnten das Angebot bis zum Sommer weiter ausbauen.

Obwohl die neueren Impfstoffe nicht die gleiche hohe Gesamtwirksamkeit zeigten wie Moderna und Pfizer im letzten Jahr und zwei noch keine Ergebnisse aus ihren klinischen Studien in den USA gemeldet haben, haben mehrere Impfstoffexperten auf ein übersehenes, aber vielversprechendes Detail hingewiesen: Alle Die Impfstoffe haben einen hervorragenden Schutz gegen die schwere Form von Covid-19 gezeigt, die zu Krankenhausaufenthalten und zum Tod führt.

“Was ich vermeiden möchte, ist, dass Menschen bis zum Krankenhausaufenthalt krank werden oder auf tragische Weise von Covid-19 sterben”, sagte Dr. Stefan Baral, Epidemiologe an der Johns Hopkins Bloomberg School of Public Health. Die Nachricht, dass die Impfstoffe vor diesen Ergebnissen schützen, sei “unglaublich erhebend”.

Die Herausforderung besteht jedoch darin, “an einen Punkt zu gelangen, an dem tatsächlich genug Menschen geimpft werden können, um diese Vorteile auf Bevölkerungsebene zu sehen”, sagte Angela Rasmussen, Virologin am Center for Global Health Science and Security der Georgetown University. “Meine derzeit größte Sorge ist, dass die Menschen nicht die Vorsichtsmaßnahmen treffen, die sie kurzfristig treffen sollten, damit wir in den kommenden Monaten bequem an diesen Punkt gelangen können.”

Experten haben gesagt, es sei noch zu früh, um die allgemeinen Auswirkungen der Massenimpfung auf die öffentliche Gesundheit in den USA zu erkennen. Aber ein anderes Land – Israel – bietet Hoffnung. Forscher in diesem Land, das weltweit führend bei der Impfung seiner Bevölkerung ist, haben nach nur einer Dosis Pfizers Schuss einen signifikanten Rückgang der Infektion und nach zwei Schüssen bessere Ergebnisse als erwartet gemeldet, vorläufige Daten, die Experten als ermutigend beschrieben haben.

“Dies ist, was passieren kann, wenn die Dinge richtig laufen”, sagte Dr. Iwasaki aus Yale.

Um dieses Ziel zu erreichen, müssen die Vereinigten Staaten jedoch schnell handeln und das Virus in Schach halten, da hoch ansteckende Varianten häufiger auftreten.

Die Gesundheitsbehörden müssen auch den Zugang zu den Impfstoffen für diejenigen verbessern, die am anfälligsten für Covid-19 sind. Frühe Impfdaten, die unvollständig sind, zeigen, dass Menschen aus wohlhabenderen, weißen Gegenden Impfterminsysteme überflutet haben und einen übergroßen Anteil am begrenzten Angebot haben.

Die gleiche Dynamik spielt sich auch global ab. Wohlhabende Länder haben einen Großteil des weltweiten Impfstoffangebots gekauft, was bedeutet, dass viele ärmere Länder bei der Impfung ihrer Bürger wahrscheinlich zurückbleiben werden. Am Mittwoch kündigte ein internationales Programm zur kostengünstigen oder kostenlosen Lieferung von Covid-19-Impfstoffen an Länder auf der ganzen Welt Pläne an, bis zum 30. Juni mehr als 300 Millionen Dosen abzugeben. Dies reicht jedoch nicht aus, um alle zu impfen.

“Ich denke, in der reichen Welt haben wir ein gutes Gefühl für Impfstoffe, aber weltweit ist es eine andere Geschichte”, sagte Marc Lipsitch, Professor für Epidemiologie und Direktor des Zentrums für Dynamik übertragbarer Krankheiten an der Harvard TH Chan School of Gesundheitswesen.

Dr. Baral von Johns Hopkins kümmert sich um die Bewohner mehrerer Obdachlosenunterkünfte in Toronto. Letzten Monat, sagte er, habe er Bewohner in einem Tierheim für ältere Männer geimpft. “Es war dieses unglaubliche Gefühl der Erleichterung – man konnte es auf ihren Gesichtern sehen”, sagte er. “Wir sind an einem anderen Ort als vor sechs Monaten.”

Categories
Health

American Airways to ship employees furlough notices once more with journey demand low

American Airlines to send staff furlough notices again with travel demand low

American Airlines announced Wednesday that it will be sending vacation notices to approximately 13,000 employees this week as a second round of government payroll assistance expires next month and demand for travel continues to be in ruins.

“The vaccine is not being distributed as quickly as neither of us anticipated, and new restrictions on international travel requiring customers to test negative for COVID-19 have dampened demand,” wrote Doug Parker, CEO of American, and Robert Isom, President, in a note to staff.

Rival United Airlines sent similar vacation alerts to 14,000 employees last Friday.

The last $ 15 billion congress, approved for U.S. airlines late last year, urged airlines to call back employees on leave in the fall and keep payroll up through March 31. This was the second round of Covid aid to the industry. Congress gave airlines $ 25 billion last March to keep them from downsizing in the fall.

The airline unions are now seeking more than $ 15 billion in support for the industry’s payroll to keep jobs through Sept. 30, and Americans Parker and Isom said they are backing another round of aid.

“We are fully behind our union leaders’ efforts to fight for an extension and we will use our time and energy to support that effort in any way we can,” they said.

After the U.S. airline’s CEOs reported new record losses of $ 34 billion last month, they warned they wouldn’t expect a sharp recovery in air travel anytime soon.

Employers are legally obliged to give staff 60 days in advance of any possible layoffs or temporary vacation days. The communications do not guarantee that recipients will ultimately lose their jobs.

American offers early retirement programs for employees who have been in their workgroups for more than 10 years, including up to $ 150,000 for a retirement reimbursement package and some travel benefits. Absence leave for one year or 18 months with partial remuneration will also be introduced.

“Obviously, issuing these required WARNINGS is not a step we want to take,” said Parker and IsomHelp. “Ten Thousands of our colleagues have faced extreme uncertainty about their job security in the past 12 months. This adds to the emotional stress that our entire team was exposed to during an incredibly difficult year. “

American CEO Parker warned employees last week that the airline is still overstaffed for current demand forecasts and that vacation days may be on the way.

Categories
Health

After a Rocky Begin, Novavax Vaccine May Be Right here by Summer time

After a Rocky Start, Novavax Vaccine Could Be Here by Summer

Dr. Thomas Campbell, who oversees the testing site at UCHealth in Colorado, said he had received more than 2,000 emails and hundreds of calls from potential volunteers. He said the excitement about Pfizer and Moderna vaccines has piqued interest in vaccination, but their scarcity is leading some people to investigate other options. The news about the Novavax trial in Great Britain has also sparked excitement: so far, 224 people have registered at his location.

“If they’re in a clinical trial with an experimental vaccine, they may get a vaccine sooner than usual,” he said.

If Novavax is successful, the new vaccine could add to an expanded portfolio of vaccinations in the US by late spring. Moderna and Pfizer have agreements with the United States to deliver 400 million doses by the middle of the year, enough to fully vaccinate 200 million people, and both companies are in talks to deliver an additional 100 million doses each after that.

Johnson & Johnson, who recently reported that its single-dose vaccine was effective in a large US study, could get approval this month but may not be able to ship any significant quantities to the US until April. AstraZeneca’s U.S. study is also ongoing, and the company has signed a deal to provide Americans with 300 million doses of its two-shot vaccine.

But any number of obstacles could affect Novavax’s progress. As other vaccines became more widespread, participants in the Novavax study could drop out. Although the results in the UK were promising, the US study could produce different results. Or the company might fail to demonstrate to regulators that it can reliably manufacture its vaccine on a large scale. With the US likely to have three approved vaccines available to the public soon, the company is under pressure to move forward or at risk of losing ground to competitors.

Novavax, based in Gaithersburg, Md., Struggled for years to get a successful product to market, and in 2019 its stock traded so low it was in danger of being delisted from the Nasdaq. Then, last spring and summer, two big deals saved it from doom. In May, the Coalition for Epidemic Preparation Innovations awarded the company up to $ 388 million to make its Covid vaccine available worldwide. In July, it was selected by the federal government’s Operation Warp Speed ​​program to develop and sell its vaccine to the United States. Later in the summer, the company reported encouraging results in preliminary studies.

However, the company struggled last fall to begin the U.S. process with its previous October target. Novavax has put great emphasis on manufacturing and has plants around the world. However, making these vaccines is a delicate and unpredictable process even for seasoned drug makers, and Novavax has struggled to outgrow the smaller batches required for early studies.

Categories
Health

Israel giving 5,000 Covid vaccine doses to Palestinians is insufficient: HRW

A guide on what we know so far

Palestinian students wearing face masks stand in line to enter their school after personal training, interrupted as part of the new type of coronavirus (Covid-19) measures, resumed for elementary and secondary school students in the Gaza Strip today on January 13, 2021.

Ali Jadallah | Anadolu Agency | Getty Images

Israel’s decision to give 5,000 doses of the coronavirus vaccine to frontline Palestinian health workers has been criticized by Palestinians and right-wing groups as inadequate and inconsistent with the country’s commitments.

“Israel’s delivery of 5,000 doses of vaccine to Palestinian health workers pales in comparison to the nearly 5 million doses it has already provided to Israeli citizens,” Omar Shakir, Israeli and Palestinian director of Human Rights Watch, told CNBC after the announcement. Just over 5 million people live in the Palestinian Territories.

The office of Israel Defense Minister Benny Gantz announced that the broadcast was approved on Sunday. This was the first such step since the Pfizer BioNTech vaccine began shipping through the 9 million country in mid-December. Israel has since run the world’s fastest vaccination campaign in terms of shots per person, and says more than a quarter of its population has received at least the first dose of vaccine since December 19.

In this aerial photo, taken in Tel Aviv, Israel, on Monday January 4, 2020, people are queuing outside a Covid-19 mass vaccination center in Rabin Sqaure. Israel plans to vaccinate 70% to 80% of its population by April or May. Health Minister Yuli Edelstein has said.

Bloomberg | Bloomberg | Getty Images

The Palestinian Authority did not comment on the news. Until the last announcement, however, no vaccines had reached the Palestinians, except for those who lived in East Jerusalem or worked in the Palestinian hospitals there.

“Israel retains overall control”

For rights organizations and Palestinian interest groups, this was a breach of duty by Israel, which the United Nations has classified as an occupying state over the Palestinian territories.

“Israel retains overall control over land, over the population register, over the movement of people and goods and over the airspace. Under international law, this type of control is linked to obligations towards an occupied population,” said Shakir.

“Israel’s obligations under international law after more than 50 years of occupation, the end of which is not in sight, go far beyond the supply of some vaccines if they have the capacity,” he added, “but rather offer the Palestinians in the occupied territory equal access to the vaccine on par with what it offers its own citizens. “

A health care worker administers a Covid-19 vaccine at Clalit Health Services in the ultra-Orthodox Israeli city of Bnei Brak on January 6, 2021.

JACK GUEZ | AFP | Getty Images

The Israeli health and foreign ministries did not respond to CNBC’s requests for comments in response to these specific statements, but previously stressed that the Israeli coordinator of government activities in the territories had been working with the Palestinian Authority to provide ventilators, test kits and other medical devices to transfer “Donated by the international community.”

There was also joint training of some Israeli-Palestinian medical teams, COGAT told CNBC.

However, Israeli officials argue that ultimate responsibility for health care and vaccine acquisition rests with the Palestinian Authority, which the Palestinians have elected to be the government of the West Bank.

Human Rights Watch’s Shakir denies this. “The fact that Palestinians also bear responsibility does not negate the Israeli role. Ultimately, as occupying powers, they are responsible for the supply and well-being of the occupied population,” he said.

“The hospitals are full of patients”

Nouar Qutob, assistant professor and Covid-19 data researcher at Arab American University in the city of Ramallah on the West Bank, is concerned about the situation.

“Things are worrying. We have cases, cases we don’t know about, the hospitals are already full of patients. And the British variant is now in Palestine,” Qutob told CNBC, referring to a new strain of the first identified coronavirus in the UK and found to be 70% more communicable.

As a resident of East Jerusalem, Qutob has an Israeli residence and was able to receive the Pfizer vaccine. She commutes to work from home in Ramallah, which has a private Covid-19 testing center, but said the rate of people tested has decreased.

“People avoid testing because they don’t want to give up work,” she said.

A worker cleans the classes in preparation for school before teaching in person in specific classes at Taybe Schools in Khan Yunis, Gaza, October 4, 2020 on October 10, 2020.

Mustafa Hassona | Anadolu Agency via Getty Images

The new variant of the virus that now exists in the Palestinian Territories is “really worrying because it means more cases – and we still don’t have the vaccine in the West Bank,” she said. Qutob spoke to CNBC ahead of the Israeli announcement on Sunday, but since the delivery of the 5,000 doses of vaccine is only for frontline Palestinian health workers, it won’t do much to change the infection situation for the general population.

The latest data from the World Health Organization shows 178,900 confirmed coronavirus cases among Palestinians in the West Bank, East Jerusalem and the Gaza Strip, with more than 2,000 deaths.

The Palestinians expect the first major vaccine shipments in March

The Palestinian Authority expects to receive its first shipments of independently sourced vaccines in March.

Yasser Bouzia, an official with the Palestinian Ministry of Health, told CNBC that the PA is currently in a bilateral agreement with AstraZeneca for 2 million doses of its UK-developed vaccine. An additional 2 million vaccine doses are expected to be received through COVAX, a global program established to ensure equitable access to vaccines around the world.

“That will cover almost the majority of the population. And after that we will look to other sources to get nearly 1 million more people vaccinated because we want to vaccinate nearly 5.2 million people,” said Bouzia.

Until then, the infections will still spread despite government restrictions.

“People don’t seem to want to abide by the closings and regulations, they just suffer from bad economic situations,” said Qutob. “I don’t see people following the rules and the virus is spreading, and it’s worrying.”

Categories
Health

W.H.O. consultants investigating the origin of the virus go to a lab in Wuhan.

W.H.O. experts investigating the origin of the virus visit a lab in Wuhan.

A team of experts from the World Health Organization studying the causes of the pandemic visited a research center in Wuhan, China on Wednesday that has been the subject of several unsubstantiated theories about the coronavirus.

WHO scientists met with staff at the center, the Wuhan Institute of Virology, which houses a state-of-the-art laboratory known for its research on coronaviruses.

The institute came under scrutiny last year when the Trump administration advocated the unsubstantiated theory that the virus may have leaked from a government-run laboratory in China. But many high-ranking American officials have privately said that evidence suggesting a laboratory accident is primarily circumstantial.

Most scientists agree that the coronavirus most likely occurred in nature and spread from animals to humans. Peter Daszak, one of the experts on the WHO team, described the conversation on Wednesday at the Wuhan Institute as open. “Important questions asked and answered,” he wrote on Twitter, without giving details.

One of the people the WHO team met was Shi Zhengli, known as China’s “bat woman” for her study of coronaviruses found in bats. In June, Dr. Shi first voiced fears that the virus may have leaked from the lab, according to an interview with Scientific American. Later checks showed that none of the gene sequences matched the viruses examined by the staff.

Separately, China announced on Wednesday that it would provide 10 million Covid-19 vaccines to Covax, a global body promoting equitable access to coronavirus vaccinations.

The decision is “another important step China has taken to promote fair distribution of vaccines,” said Wang Wenbin, a foreign ministry spokesman.

He also said the World Health Organization has started reviewing emergency vaccine approval. It was unclear what vaccines Mr. Wang was referring to. Two vaccines – manufactured by Chinese companies Sinovac and Sinopharm – have been approved for use in China.

Categories
Health

Pfizer PFE This autumn 2020 earnings fall brief, however income beats expectations

Pfizer PFE Q4 2020 earnings fall short, but revenue beats expectations

Pfizer said Tuesday it expects to sell about $ 15 billion in coronavirus vaccine doses this year and make a profit on the high 20% sales margin for the vaccinations.

At the time of its fourth quarter earnings release, Pfizer was forecasting revenue of between $ 59.4 billion and $ 61.4 billion for this year and anticipating high pre-tax adjusted earnings of 20% for the vaccine.

The company also raised its full-year earnings guidance from $ 3.10 to $ 3.10-3.20, citing “additional improvements” to its guidance for vaccine sales.

According to Refinitiv’s average estimates, Pfizer performed in the fourth quarter compared to Wall Street expectations.

  • Adjusted EPS: 42 cents compared to 48 cents expected.
  • Revenue: $ 11.68 billion versus $ 11.43 billion expected.

Revenue rose 12% from $ 10.44 billion in the same quarter last year to $ 11.68 billion – better than analysts expected.

Pfizer shares were down 2.8% in midday trading.

“As a company, we have seen the culmination of Pfizer’s decades of transformation into a pure science and innovation-driven company,” said CEO Albert Bourla in a press release. “Our ability to move forward quickly and use the latest scientific knowledge to address the world’s major medical challenges has been tested by the COVID-19 pandemic.”

The company’s Covid-19 vaccine, which it makes together with German partner BioNTech, was the first to be approved for emergency use in the United States

Pfizer, like other Covid vaccine manufacturers, is struggling to meet demand for shots which, hopefully, will help end the pandemic. Recently, the French pharmaceutical company Sanofi was asked for help with making cans.

In slides released ahead of the earnings call, Pfizer plans to ship 200 million doses of its coronavirus vaccine to the U.S. by May, earlier than originally forecast in July.

The company also said it could potentially deliver 2 billion doses globally by the end of this year, as healthcare providers can extract an additional sixth dose of the vaccine from the vials. In December, the Food and Drug Administration announced that additional doses from vials could be used after the cans were discarded due to labeling confusion.

The company also said Tuesday it would be “ready to respond” if a variant of Covid shows evidence of bypassing its vaccine. In the past few weeks, U.S. health officials, including Dr. Anthony Fauci, raised concerns that vaccines currently on the market may not be as effective against new, more contagious strains of the virus.

Novavax said Thursday its vaccine was only 49% effective against B.1.351, the highly contagious strain in South Africa. Johnson & Johnson also said its vaccine was less effective against the strain. On Friday, his one-time vaccine was 66% effective overall, but only 57% in South Africa.

A study conducted by Pfizer found that the new, highly contagious strains in the UK and South Africa had little impact on the effectiveness of the vaccine. Nevertheless, Pfizer is developing a booster shot to protect itself from the new variants. Moderna and Novavax are also developing modified vaccines.

In the slides, Pfizer said that patients “likely need regular boosting to maintain the immune response and counter newly emerging variant strains.”